UBS Maintains Buy on HCA Healthcare, Lowers Price Target to $579

Benzinga Newsdesk www.benzinga.com Negative 49.5%

Neg 49.5% Neu 0% Pos 0%

UBS analyst A.J. Rice maintains HCA Healthcare (NYSE:HCA) with a Buy and lowers the price target from $635 to $579.

Comments

No comments yet. Be the first!